Home Featured Page 301

Featured

Latest

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal

Tryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing Program

Comparing 18-MC vs. Ibogaine for the Treatment of Substance Use Disorder

The Nuances of Ketamine’s Neurochemistry

What Is Peyote? Everything You Need to Know About Mescaline Cactus

Psychedelics Research Review: January 2021

ATMA Launches Canada’s First Psychedelic Training Program for Mental Health Professionals...

Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including...

Psychedelic Bulletin: DMT for Stroke; MindMed’s Drug Discovery Partnership; Psychedelics are...

Psychedelic Business News Spotlight: February 12, 2021

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal

Tryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing Program

Comparing 18-MC vs. Ibogaine for the Treatment of Substance Use Disorder

The Nuances of Ketamine’s Neurochemistry

What Is Peyote? Everything You Need to Know About Mescaline Cactus

Psychedelics Research Review: January 2021

ATMA Launches Canada’s First Psychedelic Training Program for Mental Health Professionals...

What Drug Is Best for Sex?

Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including...

Psychedelic Bulletin: DMT for Stroke; MindMed’s Drug Discovery Partnership; Psychedelics are...

Psychedelic Business News Spotlight: February 12, 2021

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY